▲ 0.69%
prev close
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
Congressional Trades
2
All tracked trades
Members Trading
2
Unique members
Net Activity
-2
0 buys · 2 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2024-09-04 | ICLRICON plc - Ordinary Shares | Sell | $1,001 - $15,000 | 573d ago | — | |
| 2023-01-31 | ICLRICON plc - Ordinary Shares | Sell | $1,001 - $15,000 | 1143d ago | — |
2024-09-04
John James
ICLR
Amount
$1,001 - $15,000
Filed
573d ago
2023-01-31
Kevin Hern
ICLR
Amount
$1,001 - $15,000
Filed
1143d ago
Recent News
Powered by Polygon.io
ICLR SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer
Clinical Trials Support Software Solutions in a $34.15B Trial Economy by 2035
GEMI ALERT: Gemini Space Station Shareholders Should Contact Block & Leviton To Potentially Recover Losses
Clinical Research Provider Icon Stock Crashes On Accounting Probe
Trade Timeline
Congressional activity, newest first
John James
2024-09-04 · Sale
$1,001 - $15,000
Kevin Hern
2023-01-31 · Sale
$1,001 - $15,000